Genitourinary Cancers Symposium

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.

Phase 3 MAGNITUDE study results show positive efficacy for niraparib plus abiraterone in HRR gene-altered metastatic castration resistant prostate cancer.

A look back at apalutamide treatment in the the TITAN and SPARTAN trials showed that deep prostate-specific antigen responses lead to improvement in certain health-related quality of life factors.

According to real-world data, apalutamide may be more likely to offer an early and deep prostate-specific antigen reduction than enzalutamide.

Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.

The addition of the oral hypoxia-inducible factor 2α inhibitor belzutifan to cabozantinib led to disease control in a majority of patients with previously treated advanced clear cell renal cell carcinoma, according to preliminary results from a phase 2 trial presented at the 2021 Genitourinary Cancers Symposium.

Cabozantinib reduced the risk of disease progression or death by 40% in comparison with sunitinib in patients with metastatic papillary renal cell carcinoma, according to findings from the randomized phase 2 SWOG 1500 study.

An increase in metastatic prostate cancer cases were reported in the United States and investigators are suggesting that this may be due, in part, to reductions in prostate-specific antigen, according to epidemiologic data from a study presented during the 2021 Genitourinary Cancers Symposium.

In patient with metastatic renal cell carcinoma who have brain metastases, treatment with cabozantinib displayed significant intracranial and extracranial, results from a retrospective analysis presented during the 2021 Genitourinary Cancers Symposium show.

A molecular signature has been identified that can characterize long-term responders from treatment with apalutamide and androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, according to findings, presented at the 2021 Genitourinary Cancers Symposium.

In patients with non-muscle invasive bladder cancer carcinoma in-situ who were unresponsive to Bacillus Calmette-Guerin, the addition of N-803 induced a high rate of complete responses, findings from a cohort of the phase 2/3 QUILT-3.032 study showed.

Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.

Patrick G. Pilié, MD, explains how the safety profile of darolutamide, as seen in the ARAMIS clinical trial, differs from those of enzalutamide and apalutamide.

Apalutamide in combination with androgen deprivation therapy led to a reduction in the risk of death of 35% in comparison with ADT alone for patients with metastatic castration-sensitive prostate cancer in a final analysis of the phase 3 TITAN trial.

Results from the phase 3 CheckMate-274 trial showed that nivolumab following surgery improved disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma, according a presentation given during the 2021 ASCO Genitourinary Cancer Symposium.

Enfortumab vedotin demonstrated superior efficacy compared with chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based chemotherapy and PD-1/L1 inhibition, according to results from a primary analysis of the phase 3 EV-301 clinical trial.

Response rates to enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors were the highest numerically observed for any regimen, according to findings from study EV-201 presented at the 2021 American Society of Clinical Oncology Genitourinary Cancer Symposium.

Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.

Nivolumab in combination with cabozantinib continues to demonstrate superior efficacy over sunitinib monotherapy in the frontline treatment of patients with advanced renal cell carcinoma, according to extended follow-up data from the phase 3 CheckMate 9ER trial.

A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.

In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.

The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.

Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.

A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.

In the phase 3 ACIS study, the addition of apalutamide to abiraterone acetate lead to a reduction in the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that Japanese patients with advanced urothelial cancer whose disease did not progress on frontline chemotherapy benefited from the addition of avelumab to best supportive care in the first-line maintenance setting.

Response rates in patients with metastatic urothelial carcinoma were boosted when the novel PI3K-y inhibitor eganelisib was added to nivolumab, according to recent research presented during the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.

In patients with clear cell renal cell carcinoma who had been treated with an immune checkpoint inhibitor in prior lines of therapy, lenvatinib in combination with everolimus was found to be safe and effective.

In an interview with Targeted Oncology, Martin T. King, MD, PhD,discusses INTREPId following his poster presentation of the trial design at the 2020 Genitourinary Cancer Symposium. He also discusses other another promising studies being presented at the conference.